Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2…

Overview of attention for article published in The Journal of Headache and Pain, October 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

So far, Dimensions has found 63 publications that cite this research output.

Article in BMJ Neurology Open (April 2024)

Article in Frontiers in Neurology (March 2024)

Article in The Journal of Headache and Pain (February 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.